Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Rare Disease Policy Needs To Help Revive Abandoned Candidates & Repurpose Existing Drugs

Executive Summary

The EU must adopt a more comprehensive policy on rare diseases to increase the number of orphan drugs and address access challenges, says EURORDIS’ chief executive Yann Le Cam.

You may also be interested in...



Creating A ‘Critical Mass’: Outgoing EURORDIS Chief On 25 Years Of EU Orphan Disease Policy

As Yann Le Cam prepares to step down from his role as leader of the EU network of rare disease patient organizations, EURORDIS, he reflects on the organization’s role in almost three decades of major changes to Europe’s orphan disease and drug policy.

MSD & Kyowa Question NICE’s Processes After English Funding Rejected For Rare Disease Drugs

MSD and Kyowa Kirin have separately criticized England’s HTA body, NICE, for assessing their respective rare disease medicines Welireg and Crysvita using its standard appraisal pathway. Both medicines were provisionally rejected for reimbursement.

Germany To Increase Data Requirements For Pricing Orphan And Other Drugs

A new bill going through the German legislative process could oblige manufacturers of orphan drugs and certain other products to submit real-world data from registries that would impact pricing.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel